ClinicalTrials.gg
CompletedNCT06111287IMPACTUpdated Nov 1, 2023

Outcomes of Trasversus Abdominis Release for Complex Abdominal Wall Hernia

An observational study in Hernia, Abdominal and Hernia Incisional, sponsored by Azienda Sanitaria Locale Napoli 2 Nord. Completed at 2 sites in Italy. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2023-11-01.

Sponsored by Azienda Sanitaria Locale Napoli 2 Nord · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
432
Ages
16 Years and older
Sex
All
01

Study summary

This multicenter retrospective study analyzed data from 308 patients who underwent open Posterior Component separation with Trasversus release for primary or recurrent complex abdominal hernias between 2015 and 2020. The primary endpoint was the rate of Hernia Recurrence and Mesh Bulging at 3, 6, 12, 24, and 36 months. Secondary outcomes included surgical site events and were assessed using the Pain scale.

Read the detailed description

Study design This study is reported according to the STROBE statement for cohort studies A retrospective multicentric study was conducted to analyze the surgical outcomes of patients undergoing open with Posterior Component separation with Trasversus release for inisional hernia. It was conducted according to the ethical principles stated in the Declaration of Helsinki. Written informed consent was obtained from all subjects.

Study setting and study population From January 2015 and May 2020, all the patients affected by primary or recurrent complex abdominal hernias undergoing open Posterior Component separation with Trasversus release referring to 6 centers, were considered for enrollment in the study. Inclusion criteria were age ≥16 years, primary or recurrent complex abdominal hernias with more than >10 cm midline defects Exclusion criteria were follow-up data lower than 36 months, patients with a stoma for whom closure was not planned during the abdominal hernia repair

02

Conditions studied

  • Hernia, Abdominal
  • Hernia Incisional
03

In context

Hernia, Abdominal

82 studies on the registry are indexed under Hernia, Abdominal; 19 are open to participants now.

This study's enrollment of 432 is above the median of 115 across 29 observational studies indexed under Hernia, Abdominal.

Browse Hernia, Abdominal studies →

Lead sponsor

Azienda Sanitaria Locale Napoli 2 Nord is the lead sponsor of 16 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

From January 2015 and May 2020, all the patients affected by primary or recurrent complex abdominal hernias undergoing open component posterior separation with trasversus abdomen release referring to 6 centres, were considered for enrollment in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age ≥16 years,
  • primary or recurrent complex abdominal hernias with more than >10 cm midline defects

Exclusion criteria

Exclusion Criteria:

  • follow-up data lower than 36-months, patients with a stoma for whom closure was not planned during the abdominal hernia repair
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
432 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Hernia Recurrence

    In details, Hernia Recurrence was clinically defined as any visible or palpable ''blowout'' in the abdominal wall. computed tomography scan evaluation was carried out by a radiologist with 10 years of gastrointestinal computed tomography scan experience.

    Time frame: 3 months

  2. Hernia Recurrence

    In details, Hernia Recurrence was clinically defined as any visible or palpable ''blowout'' in the abdominal wall. computed tomography scan evaluation was carried out by a radiologist with 10 years of gastrointestinal computed tomography scan experience.

    Time frame: 6 months

  3. Hernia Recurrence

    In details, Hernia Recurrence was clinically defined as any visible or palpable ''blowout'' in the abdominal wall. computed tomography scan evaluation was carried out by a radiologist with 10 years of gastrointestinal computed tomography scan experience.

    Time frame: 12 months

  4. Hernia Recurrence

    In details, Hernia Recurrence was clinically defined as any visible or palpable ''blowout'' in the abdominal wall. computed tomography scan evaluation was carried out by a radiologist with 10 years of gastrointestinal computed tomography scan experience.

    Time frame: 24 months

  5. Hernia Recurrence

    In details, Hernia Recurrence was clinically defined as any visible or palpable ''blowout'' in the abdominal wall. computed tomography scan evaluation was carried out by a radiologist with 10 years of gastrointestinal computed tomography scan experience.

    Time frame: 36 months

  6. Mesh Bulging

    In details, Mesh Bulging was clinically defined as any visible or palpable ''blowout'' in the abdominal wall. computed tomography scan evaluation was carried out by a radiologist with 10 years of gastrointestinal computed tomography scan experience.

    Time frame: 3 months

  7. Mesh Bulging

    In details, Mesh Bulging was clinically defined as any visible or palpable ''blowout'' in the abdominal wall. computed tomography scan evaluation was carried out by a radiologist with 10 years of gastrointestinal computed tomography scan experience.

    Time frame: 12 months

  8. Mesh Bulging

    In details, Mesh Bulging was clinically defined as any visible or palpable ''blowout'' in the abdominal wall. computed tomography scan evaluation was carried out by a radiologist with 10 years of gastrointestinal computed tomography scan experience.

    Time frame: 24 months

  9. Mesh Bulging

    In details, Mesh Bulging was clinically defined as any visible or palpable ''blowout'' in the abdominal wall. computed tomography scan evaluation was carried out by a radiologist with 10 years of gastrointestinal computed tomography scan experience.

    Time frame: 36 months

  10. surgical site events

    Regarding the surgical site events, the classification of wound events was assigned according to the likelihood and degree of wound contamination at the time of the operation, as stated in the Centre for Disease Control and Prevention wound classification (superficial, deep or organ space)

    Time frame: 1 months

  11. Number of patients affected by Superficial surgical site infection

    Superficial infections according to Clavien-Dindo criteria

    Time frame: 1 months

Secondary outcomes

  1. Number of patients affected by Superficial surgical site infections

    Superficial infections according to Clavien-Dindo criteria

    Time frame: Within 30 days postoperatively

  2. Number of patients affected by Deep surgical site infections

    Deep surgical site infections according to Clavien-Dindo criteria

    Time frame: Within 30 days postoperatively

  3. Number of patients affected by organ space infections

    Organ space infections according to Clavien-Dindo criteria

    Time frame: Within 30 days postoperatively

  4. Number of patients affected by Surgical Site Occurence

    Surgical Site Occurence Reported according to the Ventral Hernia Working Group (VHWG) definitions

    Time frame: Within 30 days postoperatively

  5. Postoperative pain

    Postoperative pain will be recorded according to the Visual Analogue Scale (VAS). The Visual Analogue Scale (VAS) measures pain intensity. The Visual Analogue Scale consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be').

    Time frame: Postoperative pain will be recorded according to visual analogue scale Visual Analogue Scale at 1 month.

  6. Postoperative pain

    Postoperative pain will be recorded according to the Visual Analogue Scale (VAS). The Visual Analogue Scale (VAS) measures pain intensity. The Visual Analogue Scale consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be').

    Time frame: Postoperative pain will be recorded according to visual analogue scale Visual Analogue Scale at 3 month.

  7. Postoperative pain

    Postoperative pain will be recorded according to the Visual Analogue Scale (VAS). The Visual Analogue Scale (VAS) measures pain intensity. The Visual Analogue Scale consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be').

    Time frame: Postoperative pain will be recorded according to visual analogue scale Visual Analogue Scale at 6 month.

  8. Postoperative pain

    Postoperative pain will be recorded according to the Visual Analogue Scale (VAS). The Visual Analogue Scale (VAS) measures pain intensity. The Visual Analogue Scale consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be').

    Time frame: Postoperative pain will be recorded according to visual analogue scale Visual Analogue Scale at 12 month.

  9. Postoperative pain

    Postoperative pain will be recorded according to the Visual Analogue Scale (VAS). The Visual Analogue Scale (VAS) measures pain intensity. The Visual Analogue Scale consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be').

    Time frame: Postoperative pain will be recorded according to visual analogue scale Visual Analogue Scale at 24 month.

  10. Postoperative pain

    Postoperative pain will be recorded according to the Visual Analogue Scale (VAS). The Visual Analogue Scale (VAS) measures pain intensity. The Visual Analogue Scale consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be').

    Time frame: Postoperative pain will be recorded according to visual analogue scale Visual Analogue Scale at 36 month.

07

Study locations

2 sites
  • Francdesco Pizza
    Napoli, Naples 80035, Italy
  • Francesco Pizza
    Naples, 80131, Italy
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: july 2024

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2015 to primary completion in May 2020, 64 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2023
First posted
Nov 1, 2023
StartActual
Jan 2015
Primary completionActual
May 2020
CompletionActual
Jul 2020
Last update
Nov 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06111287
Lead sponsor
Azienda Sanitaria Locale Napoli 2 Nord
Responsible party
Francesco Pizza (MD,PhD, Responsible for the Bariatric and Metabolic Surgery unit, Azienda Sanitaria Locale Napoli 2 Nord) — Principal investigator
First posted
Nov 1, 2023
Start date
Jan 2015
Primary completion
May 2020
Completion
Jul 2020
Last update
Nov 1, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion